could trastuzumab deruxtecan become the new standard of care for pretreated her2-positive breast...
Published 4 years ago • 2K plays • Length 7:50Download video MP4
Download video MP3
Similar videos
-
5:26
trastuzumab deruxtecan shows benefit in patients with her2 mbc
-
5:09
trastuzumab deruxtecan shows benefit across her2 metastatic breast cancer subgroups
-
1:29
tuxedo-1: trastuzumab deruxtecan for the treatment of her2-positive breast cancer brain metastases
-
5:59
trastuzumab deruxtecan for the treatment of her2 breast cancer
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
5:40
trastuzumab deruxtecan doubles pfs in metastatic breast cancer with low her2 expression
-
7:32
trastuzumab deruxtecan yields promising results in her2-positive breast cancer patients pretreat...
-
2:43
margetuximab for the treatment of her2-positive breast cancer
-
6:42
6 months trastuzumab non-inferior to 12 months for her2 positive early breast cancer
-
5:50
her2climb: investigating tucatinib with capecitabine and trastuzumab in her2-positive metastatic...
-
4:01
trastuzumab deruxtecan: a promising agent for treating her2-low breast cancer?
-
12:47
trastuzumab deruxtecan vs trastuzumab emtansine in patients with her2 metastatic breast cancer
-
5:57
phase 3 study shows her2 therapy clinically meaningful for metastatic breast cancer patients
-
5:29
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
2:12
trastuzumab deruxtecan in her2-low advanced breast cancer | nejm
-
0:56
destiny-breast04: t-dxd for patients with her2-low mbc
-
0:46
clinical trials remain underway for trastuzumab deruxtecan in her2-positive breast cancer
-
7:31
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
2:06
trastuzumab deruxtecan for breast cancer | nejm